SEARCH

SEARCH BY CITATION

References

  • 1
    Committee for the preparation of guidelines for the management of malignant skin cancer. Guidelines for the management of malignant skin cancer. Jpn J Dermatol 2007; 117: 18551925. (In Japanese.)
  • 2
    Drake LA, Dinehart SM, Farmer ER, et al. Guidelines of care for androgenetic alopecia. J Am Acad Dermatol 1996; 35: 465469.
  • 3
    Shapiro J, Price VH. Hair regrowth: therapeutic agents. Dermatol Clin 1998; 16: 341356.
  • 4
    Olsen EA. Current and novel methods for assessing efficacy of hair growth promoters in pattern hair loss. J Am Acad Dermatol 2003; 48: 253262.
  • 5
    Olsen EA. Pattern hair loss in men and women. In: Olsen EA ed. Disorders of Hair Growth: Diagnosis and Treatment, 2nd edn. New York: McGraw-Hill, 2003; 321362.
  • 6
    Olsen EA, Messenger AG, Shapiro J, et al. Evaluation and treatment of male and female pattern hair loss. J Am Acad Dermatol 2005; 52: 301311.
  • 7
    Tsuboi R. Androgenetic alopecia. Jpn J Dermatol 2008; 118: 163170 (In Japanese).
  • 8
    Takashima I, Iju M, Sudo M. Alopecia and rogenetica. Its incidence in Japanese and associated condition. In: Orfanos CE, Montagna W, Stuttgen G eds. Hair Research. Berlin: Springer Verlag, 1981; 287293.
  • 9
    Itami S. Opinion survey on hair awareness (androgenetic alopecia) in Japanese adult males. Jpn Med J 2004; 4209: 2729 (In Japanese).
  • 10
    Hamilton JB. Male hormone stimulation is a prerequisite and an incitant in common baldness. Am J Anat 1942; 71: 451480.
  • 11
    Hillmer AM, Brockschmidt FF, Hanneken S, et al. Susceptibility variants for male-pattern baldness on chromosome 20p11. Nat Genet 2008; 40: 12791281.
  • 12
    Itami S, Inui S. The role of androgen in mesenchymal epithelial interactions in human hair follicle. J Investig Dermatol Symp Proc 2005; 10: 209211.

References

References

  • 1
    Watanabe Y, Nagashima T. Results of using methyl N-trimethyl-γ-aminobutyrate chloride for the treatment of seborrhea capitis. Shinryo to Hoken 1968; 10: 4144. (In Japanese.) (Level V).
  • 2
    Izaki M, Maeda M, Sakamoto M. Effect of Methyl N-trimethyl-γ-aminobutyrate chloride on alopecia. Dermatol Urol 1968; 28: 737746. (In Japanese.) (Level V).
  • 3
    Higuchi K, Koda H. The effect of Furozin solution in alopecia – a report of clinical effect review meeting at seven facilities. Shinryo to Hoken 1970; 12: 4960. (In Japanese.) (Level V).
  • 4
    Toda K, Ota M, Ishibashi Y et al. Clinical evaluation of DS-4737 in the treatment of alopecia areata and other alopecias. Jpn Pharmacol Ther 1988; 16: 47274729. (In Japanese.) (Level III).
  • 5
    Harada S, Nakayama J, Toda K et al. Clinical evaluation of DH-3923 in the treatment of male pattern baldness and other alopecias-A multi-center open trial. J Clin Ther Med 2004; 20: 351376. (In Japanese.) (Level III).

References

  • 1
    Hotta M, Imokawa G. The hair growth effect of t-flavanone. Anti-aging series 1 (Gray hair, alopecia, and hair growth). 2005; 110112. (In Japanese.) (Level III).
  • 2
    Hotta M, Imokawa G. The hair growth effect of t-flavanone. Anti-aging series 1 (Gray hair, alopecia, and hair growth). 2005; 113115.

References

  • 1
    Tajima M. Elucidation of “adenosine,” a novel hair stimulant. Anti-aging series 1 (Gray hair, alopecia, and hair growth). 2005; 100103. (In Japanese.) (Level III).
  • 2
    Oura H, Iino M, Nakazawa Y et al. Adenosine increases anagen hair growth and thick hairs in Japanese women with female pattern hair loss: a pilot, double-blind, randomized, placebo-controlled trial. J Dermatol 2008; 35: 763767. (Level II).

References

  • 1
    Mishima Y, Toshitani S, Nakayama H et al. Efficacy of tonic containing 6-Benzylaminopurine (CTP) in humans. Skin Res 1998; 40: 407414. (in Japanese.) (Level II).
  • 2
    Takeda K, Arase S, Watanabe S, Nagashima T, Watanabe Y, Sakuma A. Clinical evaluation study of LHOP formulation in androgenetic alopecia. Nishinihon J Dermatol 1993; 55: 727734. (in Japanese.) (Level II).

References

  • 1
    Fukuzumi Y. Alopecia therapies adopted at our clinic. J Soc Study Alkaloids 2008; 34: 111114 (in Japanese.) (Level V).

References

  • 1
    Inui S, Itami S. Reversal of androgenetic alopecia by topical ketoconazol: relevance of antiandrogenetic activity. J Dermatol Sci 2007; 45: 6668. (Level V).
  • 2
    Maejima H, Saito N, Mukuno A, Katsuoka K, Abe M. Considerations regarding the effects of topical treatment with ketoconazole lotion in patients with male pattern baldness. Nishinihon J Dermatol 2007; 69: 182185. (Level III).
  • 3
    Piérard-Franchimont C, De Doncker P, Cauwenbergh G, Piérard GE. Ketoconazole shampoo: effect of long-term use in androgenic alopecia. Dermatology 1998; 196: 474477. (Level III).

References

  • 1
    Drake L, Hordinsky M, Fiedler V et al. The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia. J Am Acad Dermatol 1999; 41: 550554. (Level II).
  • 2
    Kaufman KD, Olsen EA, Whiting D et al. Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. J Am Acad Dermatol 1998; 39: 578589. (Level II).
  • 3
    Leyden J, Dunlap F, Miller B et al. Finasteride in the treatment of men with frontal male pattern hair loss. J Am Acad Dermatol 1999; 40: 930937. (Level II).
  • 4
    Roberts JL, Fiedler V, Imperato-McGinley J et al. Clinical dose ranging studies with finasteride, a type 2 5a-reductase inhibitor, in men with male pattern hair loss. J Am Acad Dermatol 1999; 41: 555563. (Level II).
  • 5
    Van Neste D, Fuh V, Sanchez-Pedreno P et al. Finasteride increases anagen hair in men with androgenetic alopecia. Br J Dermatol 2000; 143: 804810. (Level II).
  • 6
    Group TFMPHLS. Long-term (5-year) multinational experience with finasteride 1 mg in the treatment of men with androgenetic alopecia. Eur J Dermatol 2002; 12: 3849. (Level II).
  • 7
    Stough DB, Rao NA, Kaufman KD, Mitchell C. Finasteride improves male pattern hair loss in a randomized study in identical twins. Eur J Dermatol 2002; 12: 3237. (Level II).
  • 8
    Whiting DA, Olsen EA, Savin R et al. Efficacy and tolerability of finasteride 1 mg in men aged 41 to 60 years with male pattern hair loss. Eur J Dermatol 2003; 13: 150160. (Level II).
  • 9
    Price VH, Menefee E, Sanchez M, Kaufman KD. Changes in hair weight in men with androgenetic alopecia after treatment with finasteride (1 mg daily): three- and 4-year results. J Am Acad Dermatol 2006; 55: 7174. (Level II).
  • 10
    Kawashima M, Hayashi N, Igarashi A et al. Finasteride in the treatment of Japanese men with male pattern hair loss. Eur J Dermatol 2004; 14: 247254. (Level II).
  • 11
    Kawashima M, Mizoguchi M, Igarashi A et al. Long term (3 years) efficacy and safety profiles of finasteride in Japanese men with androgenetic alopecia (AGA). Jpn J Clin Dermatol 2006; 60: 521530. (In Japanese.) (Level III).
  • 12
    Olsen EA, Messenger AG, Shapiro J et al. Evaluation and treatment of male and female pattern hair loss. J Am Acad Dermatol 2005; 52: 301311.
  • 13
    D’Amico AV, Roehrborn CG. Effect of 1 mg/day finasteride on concentrations of serum prostate-specific antigen in men with androgenic alopecia: a randomised controlled trial. Lancet Oncol 2007; 8: 2125. (Level II).
  • 14
    Price VH, Roberts JL, Hordinsky M et al. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. J Am Acad Dermatol 2000; 43: 768776. (Level II).

References

  • 1
    ISHRS Practice census 2007. Extrapolated number of hair restoration procedures worldwide. http://www.ishrs.org/PDF/ISHRS_Practice_Census_Survey_Report_2007.pdf International Society of Hair Restoration Surgery. ISHRS Practice census 2007 (Level V).
  • 2
    Beehner ML. Graft survival, growth, and healing studies: studies of hair survival in grafts of different sizes. In: Unger WP, Shapiro R eds. Hair Transplantation. New York: Marcel Dekker, 2004; 261279. (Level V).
  • 3
    Lepaw MI. Therapy and histopathology of complications from synthetic fiber implants for hair replacement. A presentation of one hundred cases. J Am Acad Dermatol 1980; 3: 195204. (Level IV).
  • 4
    Sec. 895.101 Prosthetic hair fibers. Part 895 Banned Devices. Subchapter H-Medical devices. Chapter I-FDA department of health and human services. Title 21-Food and Drugs. 48 FR 25136, June 3, 1983 (Level VI).